The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Open accessAbstract
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surgical resection is recognized worldwide as the preferred treatment for patients with early stage HCC, whereas liver transplantation is indicated in those with early stage disease who are not deemed suitable for resection7,22.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, regimens including immune-checkpoint inhibitors (ICIs) are currently adopted as first-line therapies in clinical guidelines7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, clinical decisions are based on clinical factors including, but not limited to, performance status, tumour burden, liver function and comorbidities7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Now the positive results of IMbrave 050 (ref. 12) have led to a revised management algorithm for patients with early stage HCC by incorporating adjuvant therapies in this disease setting7 (Fig. 4).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationErdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
InfluentialMazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”
Research works printed but not linked: 2
- Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
- Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057
Cited by
Sorted by citations
Items 801–900 of 1,000
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan
Chang, C.-W., Hsu, W., Tseng, K., Chen, C.-Y., Cheng, P., Hung, C., Lo, G., Bair, M., Chen, C., Lee, P., et al. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08512-8 · Cited by 3
“HCC was confirmed on the basis of either histological findings or clinical diagnoses made using at least two imaging techniques (e.g., abdominal ultra-sonography, hepatic arterial angiography, contrast-enhanced dynamic computed tomography, and magnetic resonance imaging) [17, 18].”
Rodríguez-Álvarez, F., Mota-Ayala, B. Z., Villavicencio-Martínez, R., Kauffman‐Ortega, E., Téllez-Morán, L. S., Castro‐Narro, G., Ignacio-Álvarez, E., Gabutti, A., & Moctezuma‐Velázquez, C. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101545 · Cited by 3
Shuya, C., Zhou, Z., Chen, C., Li, W., Liu, J., Xu, J., Zhao, C., Yuan, Y., Xu, Z., Wu, H., et al. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03523-1 · Cited by 3
“High-risk recurrence characteristics of patients undergoing hepatectomy include poor tumor differentiation, micro-and macrovascular invasion, number of tumors greater than 3, and tumor size greater than 5 cm [12].”
BackgroundMethodInfluentialLiu, J., Zhang, X., Lin, J., Dai, C., Xie, Z., Shi, X., Zhu, B., Cui, L., Wu, Y., Jing, Y., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35224 · Cited by 3
“1,2 Although consistent with the findings of Liang, it appears that baseline HBcrAg might not be as effective in predicting outcomes in patients without cirrhosis.”
Huang, Z., Zhu, R.-H., Li, S.-S., Luo, H., & Li, K. (2024) · Insights into Imaging · doi:10.1186/s13244-024-01838-x · Cited by 3
Li, J., Liu, Y., Qiu, Y., Qu, C., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487353 · Cited by 3
Dahan, K. S. E., Yokoo, T., Mendiratta‐Lala, M., Fetzer, D. T., Davenport, M. S., Daher, D., Rich, N. E., Yang, E., Parikh, N. D., & Singal, A. G. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04674-1 · Cited by 3
“[8] Contrast-enhanced ultrasound has been proposed as another imaging modality that can be used as a second-line option for HCC diagnosis (with a sensitivity of 62–75%); however, it is not recommended for surveillance due to limited supporting evidence and issues with operator dependency.”
Self-citationLiu, C. X., Jiang, W., Sun, J., Cui, J., He, D., Cheng, S., & Jie, S. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s491733 · Cited by 3
“11,12 The most notable example is the IMbrave150 trial.”
Novel biomarker in hepatocellular carcinoma: Stearoyl-CoA desaturase 1
Chen, Y., Zhong, Z., Ruan, X., Zhan, X., Ding, Y., Wei, F., Qin, X. Y., Yu, H., & Yu, L. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.11.008 · Cited by 3
Margon, J. F., Chagas, A. L., de Mattos, Â. A., Diniz, M. A., Felga, G. E. G., Boin, I. D. F. S. F., da Silva, R. F., Garcia, J. H. P., Lima, A. S., Silva, R. C. M. A., et al. (2025) · Journal of Liver Transplantation · doi:10.1016/j.liver.2025.100258 · Cited by 3
Chung, S.-D., Yong, C., Kee, K., Lu, S., Hu, T., Wang, J., Hung, C., Chen, C., Liu, Y., Li, W., et al. (2025) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-025-03632-9 · Cited by 3
Long non-coding RNA in the regulation of cell death in hepatocellular carcinoma
Wang, J., Liu, Z.-X., Huang, Z.-H., Wen, J., & Rao, Z.-Z. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i4.104061 · Cited by 3
A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma
May, S., Stevenson, K. H., Alqarafi, B., Swe, K. L. Y., Bloom, A., Mackintosh, A., Müller, M., Γεωργακοπούλου, Α., Drake, T. M., Kiourtis, C., et al. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052301 · Cited by 3
Hepatocellular carcinoma surveillance: minimum standards
Sharma, R., Aravinthan, A. D., Qurashi, M., Stenberg, B., Marshall, A., Hollywood, C., MacDonald, D. C., Foster, G. R., Rowe, I. A. C., Franklin, J. M., et al. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102907 · Cited by 3
Chiu, S.-H., Kesselman, A. J., Delitto, D., Dhanasekaran, R., Chang, W., Kamaya, A., & Tse, J. R. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.25.33389 · Cited by 3
Antony, A., Tran, N. H., Patnam, N. G., Trivedi, K. H., Karbhari, A., Suman, G., Mukherjee, S., Jacobson, M., Kemp, B. J., Thompson, S. M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07629-w · Cited by 3
“While locoregional therapies (LRT) constitute the cornerstone for early-intermediate stage disease, advanced HCC management is increasingly defined by systemic approaches based on immune checkpoint inhibitors (ICI) and anti-angiogenic agents [2].”
Expanding Indications for Surgical Resection in Hepatocellular Carcinoma
Chang, G. Y., & Yopp, A. C. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.07.004 · Cited by 2
Sachar, Y., Congly, S. E., Burak, K. W., Mańko, A., Ko, H. H., Ramji, A. S., Rahman, H., Talia, J., Jeyaparan, J., Wong, D. W., et al. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13989 · Cited by 2
International perspectives on LI-RADS
Kierans, A. S., Aguirre, D. A., Krishan, S., Lee, J. M., Ronot, M., Wang, J., & Hecht, E. M. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04729-3 · Cited by 2
“LI-RADS CT/MRI was integrated into the American Association for the Study of Liver Disease (AASLD) clinical practice guidelines in 2018 [12], adopted by the Organ Procurement and Transplantation Network (OPTN) in 2022 (13), and endorsed by the European Association for the Study of Liver Disease…”
Yang, C., Chen, Y., Sheng, L., Wang, Y., Zhang, X., Yang, Y., Ronot, M., Jiang, H., & Song, B. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s499597 · Cited by 6
What is new in the 2024 Chinese guidelines for fatty liver disease?
Yang, R., Wong, V. W., & Fan, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1165 · Cited by 2
Tkachuk, B., Stukalin, I., Wang, Y., & Congly, S. E. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001620 · Cited by 2
Gurley, T., Hernáez, R., Cerda, V., Thomas, T., Narasimman, M., Mittal, S., Al-Hasan, M., Daher, D., & Singal, A. G. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103113 · Cited by 2
Self-citationShaikh, O. S., Yan, P., & Butt, A. A. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100689 · Cited by 2
“American Association for the Study of Liver Diseases guidance does not recommend surveillance among such patients, 6 whereas European guidelines recommend surveillance based on individual risk assessment.”
InfluentialPai, S., Singal, A. G., Hao, S., Yekkaluri, S., Pillai, A. A., Moon, A. M., Yanagihara, T. K., Kokabi, N., Brown, J., Kalaria, V. J., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101434 · Cited by 2
“…older, diagnosed with HCC by American Association for the Study of Liver Disease (AASLD) guidelines ( i.e. con fi rmation via histology or imaging characteristics consistent with LIRADS criteria), 6 and received SBRT or TARE as their initial treatment between January 1, 2008 and December 31, 2019.”
Self-citationChaudhuri, U., Thornton, C. T., Crawford, T. N., & Triplett, D. (2025) · Cureus · doi:10.7759/cureus.84487 · Cited by 2
Shilbayeh, S. A. R., El‐Baset, O. A. A., Alshabeeb, M. A., Alanizi, A. H., Khedr, N. F., & Werida, R. H. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70114 · Cited by 2
Rubin, J. B., Loeb, R., Monto, A., Wong, R. J., Cheung, R. C., Batki, S. L., Ostacher, M. J., Shen, H., Hoggatt, K. J., Satre, D. D., et al. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100711 · Cited by 2
Lee, D. H. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2025.0024 · Cited by 2
Influence of the gut microbiota on the response to immunotherapy in hepatocellular carcinoma
Wu, X., & Lee, T. K. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2025.07 · Cited by 2
Fu, S., Groothuismink, Z. M. A., Balderramo, D., de Mattos, Â. Z., Hoppe, L., Carrera, E., Ferrer, J. D., Ortíz, J. E. P., Bañales, J. M., Arrese, M. A., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101508 · Cited by 2
El‐Kassas, M., Khalifa, R., Al-Naamani, K. M., Shousha, H. I., Yilmaz, Y. N., Sanai, F. M., Almattooq, M., Labidi, A., Akroush, M., Debzi, N., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s528470 · Cited by 2
Koroki, K., Ogasawara, S., Yumita, S., Nakagawa, M., Kanzaki, H., Kobayashi, K., Inoue, M., Nakamura, M., Kanogawa, N., Kondo, T., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101509 · Cited by 2
“The REGAIN investigated new roles for regorafenib in the changing landscape of systemic therapy for advanced HCC.”
InfluentialLim, J., Kim, Y., Kim, S., & Shim, J. H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325066 · Cited by 2
“Considering that the cost-effective surveillance threshold for HCC is ≥ 1.0% per year in patients with cirrhosis, [28] further studies are necessary to establish HCC surveillance guidelines for patients with AIH, particularly those with concurrent MASLD.”
InfluentialFan, R., Shi, Y., Chen, L., Wang, C., Qian, Y.-S., Gao, Y., Wang, C., Fan, X.-T., Liu, X.-L., Bai, H., et al. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00091 · Cited by 2
“15,16 Additionally, compared to MRI, CT is a more commonly used tool for diagnosing cirrhosis, assessing decompensation, and evaluating the risk of HCC progression.”
Chakravarthy, A., Pasini, E., Zhao, X., To, J. C., Shen, S. Y., Fischer, S. E., Ghanekar, A., Vogel, A., Grant, R. C., Knox, J. J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1537087 · Cited by 2
Fontana, A. P., Russolillo, N., Maurino, L., Marengo, A., Calvo, A., Ricotti, A., Langella, S., Tesoriere, R. L., & Ferrero, A. (2025) · Cancers · doi:10.3390/cancers17152556 · Cited by 2
“To date, approximately half of patients diagnosed with hepatocellular carcinoma present with disease stages that are not amenable to curative treatment, according to the most widely accepted international guidelines [1,4–8].”
Cancer‑associated fibroblasts in human malignancies, with a particular emphasis on sarcomas (Review)
Benešová, I., Kalkusova, K., Kwon, Y., Táborská, P., Stakheev, D., Krausová, K., Smetanová, J., Ozaniak, A., Bartůňková, J., Smrž, D., et al. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5785 · Cited by 3
Wang, N., Wu, Y., Xiao, M., Jie, Y., Wang, J., Wu, M., Chen, J., Sha, L., Su, Z., Chong, Y., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04194-2 · Cited by 2
“LSM follow-up was performed every 3–6 months according to the guideline by the American Association for the Study of Liver Diseases [21].”
Hoopes, J. R., Lyshchik, A. P., Xiao, T. S., Berzigotti, A., Fetzer, D. T., Forsberg, F., Sidhu, P. S., Wessner, C. E., Wilson, S. R., & Keith, S. W. (2025) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2025.06.029 · Cited by 2
Kulkarni, A. V., Singal, A. G., & Reddy, K. R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70333 · Cited by 2
Self-citationA Patient Charter to Improve Care for Hepatocellular Carcinoma
Hassan, Y., Kautz, A., James, C., Lee, D., Langenbacher, D., Bouffet, É., Chakowa, J., Hicks, J. L., Ward, J., Kuschnereit, L. A., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s526170 · Cited by 2
“Effective shared decision-making is essential for optimizing outcomes in HCC. Leading guidelines from the AASLD, 19 the EASL, 18 the APASL, 41 BCLC 29 and the ALEH, 21 suggest that HCC care decisions should be made collaboratively, considering individual preferences, overall health and treatment goals.”
InfluentialArvind, A., Kanzaki, H., Ahmed, F., Fujiwara, N., Hoshida, Y., & Singal, A. G. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70355 · Cited by 2
Self-citationNishikawa, Y., Ogino, I., Mukai, Y., Funaoka, A., TAKEDA, Y., & Hata, M. (2025) · In Vivo · doi:10.21873/invivo.14090 · Cited by 2
Sasaki, R., Abé, H., Yoshida, T., Watanabe, Y., Kimura, N., Yokoo, T., Sakamaki, A., Kamimura, H., Kamimura, K., Kanda, T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176107 · Cited by 2
Zhang, Y., Wang, D., Chen, X., Wang, Y., Zhang, G., & Liu, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1601140 · Cited by 2
Hatanaka, T., Yata, Y., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70033 · Cited by 2
Carlessi, R., Kendall, T. J., Olynyk, J. K., Dwyer, B. J., Wallace, M. C., Fallowfield, J. A., & Tirnitz‐Parker, J. E. E. (2025) · Gut · doi:10.1136/gutjnl-2025-336627 · Cited by 2
Komiyama, Y., Muraoka, M., Iijima, T., Osawa, L., Takada, H., Suzuki, Y., Sato, M., Takano, S., Maekawa, S., Tsuchiya, A., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70013 · Cited by 2
Tounkara, F., Sherpally, D., Mumtaz, K., Makary, M. S., Palm, R. F., & Manne, A. (2025) · Cancers · doi:10.3390/cancers17183034 · Cited by 2
“…guidelines for appropriate treatment for HCC, which include the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN) [6–8].”
Wong, N. S. M., Lee, F. A. S., Lee, V. W. Y., Chan, S.-K., Yeung, C. S. Y., Ho, C. H. M., Yip, W. W. L., Chiu, K. W.-H., Chan, M. K. H., Wong, F. C. S., et al. (2025) · Practical Radiation Oncology · doi:10.1016/j.prro.2025.05.016 · Cited by 2
Zhang, L., Zheng, T., Su, M., Zhang, X., Liu, H., Song, B., & Chen, Y. (2025) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-1890 · Cited by 2
“Identifying neoplastic PVT and accurately differentiating it from bland PVT are crucial for staging, treatment decisions, and prognosis prediction in patients with suspected or confirmed liver malignancies (2,3,6,8).”
de Barros, I. C., Fernandes, M. V., Villafuerte, S. R., & Brandão, A. B. D. M. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i9.111126 · Cited by 2
Audigier, C., Meister, F., Akkari, F. G., Tonglet, A., Frings, O., & Durán, R. (2025) · Lecture notes in computer science · doi:10.1007/978-3-032-07694-6_5 · Cited by 2
Pham, T. T. T., Ho, D. T., Nguyen, T. B., & Phan, H. T. (2025) · Discover Oncology · doi:10.1007/s12672-025-03651-4 · Cited by 2
“American Association for the Study of Liver Diseases (AASLD) [6] has recommended combining abdominal ultrasound (AUS) and alpha feto-protein (AFP) in HCC surveillance strategy, which improves early detection, curative treatment, especially survival rates of HCC patients [7].”
Prediction Model for Risk of Hepatocellular Carcinoma After Hepatitis C Viral Eradication
Hsu, W., Lo, G., Tseng, K., Lai, H., Chen, C.-Y., & Peng, C. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s548870 · Cited by 2
“The AAAPD-C model exhibited good discriminative capability in patients with and without advanced liver fibrosis for the risk of HCC in both the derivation (Figure 4a and b) and validation groups (Figure 4c and d).”
Refining the role of liver transplantation as a curative treatment for hepatocellular carcinoma
Yoh, T., Ito, T., Ogiso, S., Uchida, Y., Ishii, T., & Hatano, E. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02898-9 · Cited by 2
Wu, S., Chen, X., Ji, Y., Zhang, C., Xie, Y., & Liang, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1697608 · Cited by 2
Liu, M., Liu, C., Mok, T. N., Qi, X., & Ming, W. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70428 · Cited by 2
Jiang, S., Wang, Y., Fu, X., Lou, J., Gong, B., Liu, W., Li, Y., Sun, Y., Liu, C., Song, Z., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251386801 · Cited by 2
“23,45 Additionally, we constructed a multivariable predictive model combining AFP, PIVKA-II, and BCLC stage to demonstrate their predictive ability for long-term survival.”
Murillo, P. C., Lynch-Mejía, M. F., Ramírez-Quesada, W. E., Navarro, F. V., Jara, V. L., Cartín, S. A., Pérez, A. G., Chavarría, S. A., Madriz, F. A., Gonzalez, E., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102154 · Cited by 2
Liu, X., Zhang, Y., Narisu, N., Wu, F., Zhang, K., Sun, Y., & Gao, H. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0824 · Cited by 2
Hunold, T. M., Dahan, K. S. E., Pai, S., Singal, A. G., & Parikh, N. D. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70438 · Cited by 2
Self-citationVadivalagan, C., Zhang, J., Dai, J., Liu, S., Singal, A. G., Bass, K., Parikh, N. D., & Lubman, D. M. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00626 · Cited by 2
Self-citationAge-specific patterns and trends of primary liver cancer: a worldwide incidence analysis
Li, Y., Guo, C., Wang, H., Zhang, X., Zhao, S., Hu, J., Liu, Z., & Zhang, T. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003928 · Cited by 2
Kang, F., Wang, Y., Cai, F.-H., Wu, L., Wang, H., Han, L., Yin, Q., Bai, L., & Bian, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1697949 · Cited by 2
Zhou, Y., Wang, H., Wu, J., Shen, J., Ma, J., Li, Q., Chen, W., Lu, W., Feng, X., Yan, M.-L., et al. (2025) · Liver Cancer · doi:10.1159/000549684 · Cited by 2
External beam radiation for HCC: Ready for incorporation into guidelines?
Buckstein, M. H., & Dawson, L. A. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101683 · Cited by 2
Self-citationCheng, N., Tao, Y., Yang, J., Shen, C., Zhang, C., & Lou, B. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.118290 · Cited by 2
Jarrah, M., Deodhar, S., Quirk, L., Al-Hasan, M., Sharma, A., Bhamra, G. S., Terrell, J., Kanwal, F., Hoshida, Y., Rich, N. E., et al. (2025) · Cancers · doi:10.3390/cancers17233835 · Cited by 2
Self-citationHepatocellular carcinoma in non-cirrhotic liver: a prospective Spanish multicenter study.
Romero-Gutiérrez, M., Pascual, S., Rubio, M. G., Aracil, C., Márquez, L., Piqueras, B., Monterde, V. B., Ferrer, T., Miquel, M., Fernández, C. B., et al. (2025) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2025.11674/2025 · Cited by 2
Li, Z., Wang, Y., Chen, W., Zheng, L., Wan, W., & Wang, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149515 · Cited by 2
Rodríguez, E., Simon, P., Dhooge, S., Fernandez, M., Calafat, P., Kurpis, M., Núñez, N. G., Prieto, J. E., Saborowski, A. L., Vogel, A., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70159 · Cited by 2
“While current blood‐based protein biomarkers provide valuable diagnostic insights, they none-theless demonstrate insufficient predictive capabilities, especially for early‐stage HCC [6–8].”
Vella, R., Pagano, D., di Francesco, F., Petri, S. L., Bonsignore, P., Lorenzo, N. D., Calamia, S., Tropea, A., Vitale, I., Vella, I., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248871 · Cited by 2
“These findings align with existing evidence showing that HCC candidates—because of MELD exception points—experience lower dropout rates and higher transplant rates, even in regions with limited deceased-donor availability [1,28,29].”
InfluentialResponse evaluation to systemic therapy in HCC: Current challenges and future perspectives
Matute‐González, M., Ronot, M., Chernyak, V., Sangro, B., & Rimola, J. (2025) · Hepatology · doi:10.1097/hep.0000000000001621 · Cited by 3
“[9,49] 81] Since LR-TRA was explicitly designed for LRT, no data is currently available on its performance in the setting of systemic therapy.”
InfluentialDu, M., Wu, T., Yuan, H., Zhang, T., Liu, Z., & Chen, X. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00638 · Cited by 2
Novel Blood-Based Liquid Biopsy Approaches in Hepatocellular Carcinoma
Anand, N., Wu, S., Guo, Z., Figueroa, M. S., Jung, L., Li, M., Bhan, I., & Franses, J. W. (2025) · JCO oncology advances. · doi:10.1200/oa-25-00132 · Cited by 2
Liu, Y., Tao, L., Shen, Z., Zheng, J., Wang, Y., Chen, M., Xie, Y., Chen, H., Cai, J., Pan, H., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71445 · Cited by 2
“Notably, HSPB1 overexpression has been confirmed to inhibit erastin-induced ferroptosis, thereby promoting tumor development and metastasis [30].”
Tjeertes, J., Dostálek, M., Glaus, C., Gupta, V., Li, D., Nestler, A., Pelekanou, V., Pinkert, J., Ratih, I., Smith, E., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270814 · Cited by 2
“These include tyrosine kinase inhibitors such as sorafenib, lenvatinib, cabozantinib, and regorafenib, as well as antiangiogenic antibodies such as ramucirumab and bevacizumab ( 7 ).”
Sato‐Espinoza, K., Chrysostome, M.-L., Vierkant, R. A., Miller, H. K., Chotiprasidhi, P., Ilyas, S. I., Roberts, L. R., & Wangensteen, K. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000879 · Cited by 2
“[25] Data on comorbidities, imaging, and biochemical tests were collected from the electronic health record (EHR) system.”
Qiu, Z., Wang, G., Chen, Z., Cao, Y., Wang, G., Zhong, Z., Qiu, L., Gao, T., Li, J., Qi, H., et al. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004764 · Cited by 2
“This approach is more anatomically specific than the uniform 5 mm boundary suggested by current guidelines [ 2 , 8 , 33 ] .”
Lin, X., Zhang, S., Ong, M., Fang, J., Mu, A., Wang, K., Xu, L., Bi, X., Liu, X., Chen, Y., et al. (2026) · Liver Cancer · doi:10.1159/000550356 · Cited by 3
“For unresectable HCC, the European Association for the Study of the Liver (EASL), China Liver Cancer Staging (CNLC), and American Association for the Study of Liver Diseases (AASLD) guidelines recommend locoregional and/or systemic therapy [6–8].”
Sabbioni, S., Guerriero, P., Shankaraiah, R. C., Masatti, L., Michilli, A., Bassi, C., D’Abundo, L., Moshiri, F., Siena, B. D., Simoni, E., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02940-3 · Cited by 2
“Hence, sorafenib remains a fi rst-line therapy option in patients with contraindications for immunotherapy [8, 9].”
Cheng, M.-Q., Hu, H.-T., Wu, S., Huang, H., Lin, Y.-D., Tong, W., Lu, X.-Z., Ke, W.-P., Lu, R.-F., Xu, Q.-Q., et al. (2026) · Radiology · doi:10.1148/radiol.252252 · Cited by 2
Liver-Directed Therapy for Colorectal Cancer: Where Are We Now?
Song, Y., Jeeva, M., Liddell, R. P., Lafaro, K. J., Azad, N. S., Dawson, L. A., & Park, L. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-515562 · Cited by 2
Self-citationMinimally Invasive / Robotic Surgery for Hepatobiliary Cancer
Quach, D., Haddad, A., & Cao, H. S. T. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.12.006 · Cited by 2
Ageing with Haemophilia: Comorbidities in Focus
Rühl, H., Marquardt, N., & Oldenburg, J. (2026) · Transfusion Medicine and Hemotherapy · doi:10.1159/000550750 · Cited by 2
Dong, M., Jin, X., Zhang, L. J., Liang, Y., Cao, J., Li, C., & Huang, M. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70254 · Cited by 2
Akbulut, S., & Çolak, C. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i2.113870 · Cited by 3
“When nodules are detected, they are subsequently characterized using multiphasic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI)[23,24].”
Li, Y., Martin-Paulpeter, R. M., Chung, C. V., Aguilar, M. A., Matias, C. A., Delgado, A. B., Nair, S. S., Court, L. E., Perles, L. A., Sahoo, N., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1731259 · Cited by 2
Liu, Z., Wang, J., Wu, X., Shi, H., Ding, Y., & Liu, X. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07768-0 · Cited by 2
“Although systemic therapy has evolved rapidly, durable benefit remains limited for many patients, and classical cytotoxic chemotherapy has historically shown modest activity in HCC in part due to intrinsic chemoresistance and compromised liver reserve [4–6].”
Lee, T., Song, S. J., Ho, H. J., Wong, G. L., Hsu, Y., Wong, V. W., Yip, T. C., & Wu, C.-Y. (2026) · Liver International · doi:10.1111/liv.70534 · Cited by 2
ACR Appropriateness Criteria® Imaging After Liver Transplant
Wahab, S. A., Vij, A., Fung, A., Bashir, M. R., Cash, B. D., Hecht, E. M., Kendi, A. T. K., McGuire, B. M., Russo, G. K., Smith, E. N., et al. (2026) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2026.01.023 · Cited by 2
Civan, J. M., Force, M., Shaikh, A. R., Bodzin, A. S., & Lin, D. (2026) · Cancers · doi:10.3390/cancers18050721 · Cited by 2
“The current AASLD guideline on HCC published in 2023 advises surveillance for the detection of post-transplant HCC recurrence using multiphasic contrast-enhanced abdominal CT or MRI and chest CT scan, but notes that the optimal timing and duration of post-transplant surveillance is uncertain [7].”
Neureiter, D., Kiesslich, T., & Ocker, M. (2026) · Medical Sciences · doi:10.3390/medsci14010110 · Cited by 3
“The American Association for the Study of Liver Diseases (AASLD) does not recommend routine HCC surveillance for non-cirrhotic patients with HCV or MASLD, as the low annual incidence makes screening cost-ineffective and fails to identify a significant proportion of individuals at risk [35].”
Zhou, S.-Q., Wang, L.-N., Lw, W., Sun, L., Yang, Y.-C., Yang, Z.-Y., Wang, Z.-Y., Tian, H., Li, F., Chen, L.-L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001724 · Cited by 2
“[3] 13] Approximately 10%–40% of patients who undergo conversion therapy followed by resection achieve a pathological complete response (pCR), showing markedly superior 2-year progression-free survival (PFS) compared with their non-pCR counterparts (59.3% vs. 38.3%, p = 0.045).”
InfluentialZavareh, M. S. R., & Yang, J. D. (2026) · Gastroenterology report · doi:10.1093/gastro/goag018 · Cited by 3
Li, Y. X., Lu, S., Mao, S., Li, Q., Zou, X., Li, S., Li, X., Lu, D. B., Xu, M., Xu, H.-X., et al. (2026) · Radiology · doi:10.1148/radiol.252271 · Cited by 2
Hermán‐Sánchez, N., Fernández‐Barrena, M. G., Alañón-Martínez, P. E., Uriarte, I., Agami, R., Luque, R. M., Avila, M. A., Rodríguez‐Perálvarez, M., Lopez-Canovas, J. L., & Gahete, M. D. (2026) · Hepatology · doi:10.1097/hep.0000000000001736 · Cited by 2
CT and MRI LI-RADS Treatment Response Assessment 2024: Core Concepts for Clinical Practice
Naves, G. G., Dantas, P. P., Júnior, A. E. D. S., Gomes, M. M., Neves, Y. C. S., Rocha, M. D. S., Chernyak, V., & Polizio, R. P. (2026) · Radiographics · doi:10.1148/rg.250067 · Cited by 2
Metadata
- Authors
- Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- University Health Network (CA)
- Oregon Health & Science University (US)
- Northwestern Medical Faculty Foundation (US)
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Vanderbilt University Medical Center (US)
- Medical College of Wisconsin (US)
- Stanford Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Corresponding author
- Singal, Amit G.
- ORCID
- Venue
- Hepatology
- Published
- 2023-05-22
- Volume
- 78
- Issue
- 6
- Pages
- 1922-1965
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10663390
- OpenAlex
- W4377011124
- Cited by
- 2,052
- References
- 341
- Citations by year
- 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
- FWCI
- 346.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Boston Scientific Corporation
- Exelixis
- Incyte
- Cancer Research UK (26813)
- Eisai
- Ipsen
- Sirtex Medical
- National Institutes of Health (UL1TR001863)
- Genentech
- National Cancer Institute (P50CA062924, R01CA285544)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
- MeSH terms
- Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
